18 November 2015 - AMAG Pharmaceuticals, Inc. today received a complete response letter from the U.S. FDA for its application seeking approval for a single-dose vial of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in certain at-risk patients.

For more details, go to: http://ir.amagpharma.com/phoenix.zhtml?c=61596&p=irol-newsArticle&id=2113802